Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001708599-25-000089
Filing Date
2025-08-11
Accepted
2025-08-11 16:05:05
Documents
73
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ser-20250630.htm   iXBRL 10-Q 1010250
2 EX-31.1 ser-20250630xexx311.htm EX-31.1 9316
3 EX-31.2 ser-20250630xexx312.htm EX-31.2 9420
4 EX-32 ser-20250630xexx32.htm EX-32 4866
  Complete submission text file 0001708599-25-000089.txt   6490291

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ser-20250630.xsd EX-101.SCH 50595
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ser-20250630_cal.xml EX-101.CAL 73637
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ser-20250630_def.xml EX-101.DEF 240522
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ser-20250630_lab.xml EX-101.LAB 634374
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ser-20250630_pre.xml EX-101.PRE 437815
76 EXTRACTED XBRL INSTANCE DOCUMENT ser-20250630_htm.xml XML 843976
Mailing Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806
Business Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806 (256) 327-9630
Serina Therapeutics, Inc. (Filer) CIK: 0001708599 (see all company filings)

EIN.: 821436829 | State of Incorp.: AL | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38519 | Film No.: 251201949
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)